for the GRAVITAS Investigators C URRENT GUIDELINES RECOMmend treating patients undergoing percutaneous coronary intervention (PCI) and drug-eluting stent implantation with a combination of aspirin and P2Y 12 antagonist for at least 1 year.
Pharmacokinetic and pharmacodynamic studies have demonstrated wide interindividual variability in the concentration of active metabolite and in the magnitude of platelet inhibition achieved by recommended loading and maintenance doses of clopidogrel. [3] [4] [5] Although some of this variability is due to genetic polymorphisms that affect the functional activity of the CYP2C19 enzyme, most cannot be explained by genotype or other clinical characteristics. 6, 7 Several studies have suggested that patients with high on-treatment platelet reactivity while receiving clopidogrel are at an increased risk of cardiovascular events after PCI, including stent thrombosis. 8 We conducted the Gauging Responsiveness with A VerifyNow assay-Impact on Thrombosis And Safety (GRAVITAS) trial to determine whether high-dose clopidogrel is superior to standard-dose therapy for the prevention of cardiovascular events after PCI in patients with high ontreatment reactivity according to a point-of-care platelet function assay.
METHODS

Trial Design
GRAVITAS was a multicenter, randomized, double-blind, active-control trial. The details of the study design have been published previously. 9 Patient flow is shown in FIGURE 1. An independent data and safety monitoring board monitored the trial and had access to the unblinded data. The trial was approved by the institutional ethics committee of each participating institution as well as by the appropriate national ethics committees. All patients provided written informed consent.
Study Population
Patients were eligible to be enrolled if they had undergone PCI with 1 or more drug-eluting stents for the treatment of stable coronary artery disease or non-ST-elevation acute coronary syndromes. Race and ethnicity were selfidentified. A protocol amendment during the conduct of the study allowed for the enrollment of patients with ST-elevation myocardial infarction. Major exclusion criteria included the use of periprocedural glycoprotein IIb/IIIa inhibitors, the planned future use of oral anticoagulant therapy, and bleeding prior to platelet function measurement. Patients were also excluded if they did not receive a clopidogrel regimen around the time of PCI that ensured that they were near to or at their steady state level of inhibition at the time of platelet function measurement. Specifically, if the patient had no prior exposure to clopidogrel, a dose of 600 mg had to have been administered no later than 2 hours after PCI; patients already treated with clopidogrel must have received 75 mg daily for at least 7 days, or, if less than 7 days, they must have received a loading dose of 300 mg or more at the time that clopidogrel was initiated. Patients could not receive an additional loading dose prior to assessment of platelet function.
Study Procedures
Platelet function was measured with the VerifyNow P2Y12 test (Accumetrics, San Diego, California) 12 to 24 hours after PCI. This test has been previously described in detail. 10 In brief, t h i s t e s t m e a s u r e s a d e n o s i n e diphospate−induced platelet agglutination as an increase in light transmittance and uses a proprietary algorithm to report values in P2Y 1 2 reaction units (PRU). A higher PRU result reflects greater P2Y 12 -mediated reactivity. Specialized software developed for the trial encrypted the platelet function results to maintain double blinding. Study drug assignment was performed centrally by an interactive voice-response system. The clopidogrel and placebo were in tablet form and identical in appearance. Patients with high on-treatment platelet reactivity according to the platelet function test were randomly assigned in a 1:1 fashion to a regimen of high-dose or standard-dose clopidogrel. Highdose clopidogrel was given as a total first-day dose of 600 mg followed thereafter by a dose of 150 mg daily for 6 months. Standard-dose clopidogrel was prescribed as a loading dose of placebo followed by a dose of 75 mg and placebo tablet daily. A random sample of patients without high on-treatment reactivity was enrolled and assigned to standard-dose clopidogrel in a blinded fashion (placebo loading dose followed by a dose of 75 mg and placebo tablet daily). A permuted block design was used to select these patients over the course of the trial. Patients without high on-treatment reactivity who were not selected by the interactive voiceresponse system were not followed up. Aspirin treatment was required at a dose of 75 to 162 mg daily. Study visits and platelet function testing with the VerifyNow P2Y12 test were conducted at 30 days and 6 months.
End Points
High on-treatment reactivity was defined as 230 PRU or higher. This cutoff was chosen because it was similar to the cutoff suggested by a prior observational study that used receiver-operating characteristic (ROC) curve analysis to identify the level of on-treatment reactivity that provided the maximal sensitivity and specificity for the prediction of major adverse cardiovascular events after PCI. 11 The cutoff is also consistent with the suggested cutoffs derived by ROC curve analyses in several subsequent observational studies. [12] [13] [14] The primary efficacy variable was a composite of death from cardiovascular causes, nonfatal myocardial infarction, or stent thrombosis. All deaths were considered cardiovascular unless an unequivocal noncardiovascular cause could be established; hemorrhagic deaths were also considered to be cardiovascular. Myocardial infarction followed the American College of Cardiology definition. 15 Stent thrombosis was defined as definite or probable according to the Academic Research Consortium definitions. 16 The key safety end point was severe or moderate bleeding according to the Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO) definition. 17 All potential events were identified by site investigators. A clinical events committee blinded to treatment assignment and independent of the trial sponsor adjudicated all suspected primary efficacy end points.
Statistical Analysis
Efficacy comparisons were performed on the basis of the time to the first event according to the intention-to-treat principle. No imputation of missing data was performed; patients lost to follow-up were censored at the date of last contact. Safety analyses were carried out on data from patients who had received at least 1 dose of the study drug. Survival curves were generated by the Kaplan-Meier method, and survival differences between groups were compared by the log-rank test stratified by acute coronary syndromes. We estimated that, assuming an event rate of 5% in patients with high on-treatment reactivity treated with standard-dose clopidogrel and a withdrawal rate of 10%, 2200 patients with high ontreatment reactivity (1100 in each group) would provide 80% power to detect a 50% relative risk reduction in the rate of the primary efficacy variable at the 2-sided .05 significance level. This would translate into the expectation of 68 events to have 82% power. 9 The anticipated event rate in the active control group was based on prospective, observational studies of the relationship between high on-treatment reactivity and ischemic events. 11, 18 The event rate was further supported by the results of a large observational study reported after the trial began enrollment. 14 The estimated relative risk reduction underlying the trial's power calculation is greater than that of traditional megatrials, but we purposefully selected the patients who would be biologically most likely to have the most powerful clinical response to the intervention that was tested. 19 This estimate is also consistent with the treatment effect observed in the placebocontrolled trials of thienopyridine therapy in patients undergoing coronary intervention with bare metal stents. 20, 21 The principal secondary analysis was an observational comparison of the rate of the primary efficacy variable among the patients with and without high ontreatment reactivity treated with standard-dose clopidogrel. We estimated that 583 patients would provide 80% power at the 2-sided .05 significance level based on the assumptions above and an event rate of 2% in patients without high on-treatment reactivity.
Prespecified analyses included landmark analyses of the primary efficacy end point in patients event-free at 30 days. The statistical analysis plan also prespecified pharmacodynamic analyses of the randomized groups that included an assessment of the absolute level of on-treatment reactivity, the change in on-treatment reactivity, and the rate of high on-treatment reactivity at 30 days and 6 months using the Wilcoxon rank sum and 2 tests. Analyses were performed with SAS version 9.1.3 (SAS Institute Inc, Cary, North Carolina). Abbreviations: ACE, angiotensin-converting enzyme; ACS, acute coronary syndromes; BMI, body mass index, which is calculated as weight in kilograms divided by height in meters squared; CABG, coronary artery bypass graft; MI, myocardial infarction, PCI, percutaneous coronary intervention; PRU, P2Y12 reaction units; UA, unstable angina. a P value for the comparison of patients with or without high platelet reactivity assigned standard-dose clopidogrel. b Race was self-reported. c Defined as smoker within previous 7 days. d Renal insufficiency was defined as a calculated creatinine clearance of less than 60 mL per minute as determined by the Cockcroft-Gault equation.
RESULTS
Between July 2008 and April 2010, 5429 patients from 83 sites in the United States and Canada were screened with platelet function testing 12 to 24 hours after PCI. Of these, 2214 (40.8%) had high on-treatment reactivity and were randomly assigned to either high-dose or standard-dose clopidogrel (Figure 1) . The treatment groups were generally well balanced with regard to baseline demographic, clinical, and procedural characteristics (TABLE 1 ). An additional 586 patients without high ontreatment reactivity were selected at random and assigned to treatment with standard-dose clopidogrel. Demographic and clinical characteristics were similar between patients who were or were not selected, except more patients with prior myocardial infarction were in the selected cohort (189 [32%] vs 711 [27%], P =.01). As shown in Table 1 , there were several differences in the baseline demographics, medical history, and concomitant medications of the selected patients without high on-treatment reactivity compared with the patients in the randomized groups with high on-treatment reactivity. Clopidogrel exposure prior to enrollment was similar across all 3 treatment groups. Four patients (0.1%) were lost to follow-up.
Efficacy End Points
The rate of death from cardiovascular causes, nonfatal MI, or stent thrombosis was not different with high-dose compared with standard-dose clopidogrel in the patients with high ontreatment reactivity (25 [ In the secondary, observational comparison of patients with and without high on-treatment reactivity treated 
Safety End Points
The frequencies of bleeding events are shown in TABLE 4. Intracranial hemorrhage occurred in none of the patients with high on-treatment reactivity randomly assigned to high-dose clopidogrel, in 2 patients (0.2%) with high on-treatment reactivity randomly assigned to standard-dose clopidogrel, and in 1 patient (0.2%) without high on-treatment reactivity treated with standard-dose clopidogrel. The rate of discontinuation of study drug due to GUSTO severe or moderate bleeding was similar across all 3 groups: 8 patients (0.7%), 11 patients (1.0%) and 6 patients (1.0%), respectively.
Pharmacodynamic Outcomes
The pharmacodynamic effect of the study drug in patients randomly assigned to high-dose or standarddose clopidogrel according to the intent-to-treat principle is illustrated in FIGURE 3. vs 60%; 95% CI, 57%-63%; P Ͻ .001, respectively).
COMMENT
Pharmacodynamic studies have demonstrated wide interindividual variability in the platelet inhibitory response to clopidogrel, and observational studies have linked a poor pharmacodynamic response to cardiovascular events after PCI. 8, 22 We found that compared with the standard maintenance dose of 75 mg daily, prolonged high-dose clopidogrel therapy in a population of patients with high on-treatment reactivity after PCI provided a modest pharmacodynamic effect but did not reduce the rate of death from cardiovascular causes, nonfatal myocardial infarction, or stent thrombosis.
Several potential mechanisms may explain the lack of a beneficial treatment effect with high-dose clopidogrel. The possibility that on-treatment platelet reactivity is not a modifiable risk factor for thrombotic events after PCI cannot be excluded. However, undertreatment may explain our findings because high-dose clopidogrel resulted in only a modest reduction in the level of on-treatment reactivity and in the rate of high on-treatment reactivity compared with standard-dose clopidogrel. This observation is consistent with previous smaller studies demonstrating that clopidogrel 150 mg daily provides only a moderate increase in platelet inhibition above that provided by 75 mg daily in patients with high ontreatment reactivity, and that heightened platelet reactivity persists in a large proportion of patients. [23] [24] [25] [26] [27] Carriers of a reduced function CYP2C19 allele are at greater risk for high on-treatment platelet reactivity while taking clopidogrel, 6 and higher-dose clopidogrel may have only a marginal pharmacodynamic effect in these patients, especially in homozygotes. 25, 28, 29 It is possible that other more potent inhibitors of platelet aggregation may have been beneficial. Prasugrel has a strong and consistent pharmacodynamic effect in clopidogrel nonresponders 30 and is not affected by genetic variation of the CYP2C19 enzyme. 31 The clinical impact of prasugrel in patients with high reactivity while receiving clopidogrel is currently being examined in an ongoing clinical trial (clinicaltrials.gov, NCT00910299).
The relative benefit of high-dose clopidogrel may also have been diluted by the decrease in the frequency of high on-treatment reactivity in both randomized groups over the initial 30 days after PCI. High on-treatment reactivity measured 12 to 24 hours after PCI resolved at the 30-day follow-up in 38% of the patients randomly assigned to standard-dose clopidogrel. A possible explanation for this decrement in reactivity in the post-PCI period may be that early high on-treatment reactivity is a manifestation of poststenting platelet activation in a subset of patients. 32 The clinical, procedural, and genetic predictors of the early resolution of high on-treatment reactivity after PCI deserve further evaluation. The dynamic nature of platelet reactivity that was observed underscores the importance of understanding the effect of the timing of measurement on the level of reactivity and its association with adverse outcomes.
In a secondary, nonrandomized, observational comparison within the current trial, there was a numerically greater rate of the composite end point in patients with high on-treatment reactivity 12 to 24 hours after PCI. However, the low event rates and modest sample size reduced the power of the study to identify statistically significant differences. Many prior studies have documented a consistent and significant association between ontreatment reactivity and early and late cardiovascular events, and several studies have demonstrated the prognostic utility of the platelet function test used in the current study. 8, [12] [13] [14] 18, 22, [33] [34] [35] [36] [37] The prognostic strength of a single measurement of platelet reactivity after PCI may be weakened by the diminution of platelet reactivity that we observed at 30 days after PCI. This observation, combined with the variable pharmacodynamic response to high-dose clopidogrel, suggests that rather than prescribing a fixed, higher dose of clopidogrel based on a single post-PCI platelet function test, a strategy of repeated platelet function testing may have merit, and this hypothesis should be explored further.
The duration of treatment with highdose maintenance clopidogrel in the present trial is substantially longer than previously examined. We found that treatment with a 6-month post-PCI regimen of high-dose clopidogrel did not appear to be accompanied by an excess of severe or moderate bleeding events or intracranial hemorrhage compared with a standard-dose regimen. This clinical finding is consistent with our pharmacodynamic observation that high-dose clopidogrel provided only a modest amount of incremental platelet inhibition in patients with high ontreatment reactivity. The Clopidogrel and Aspirin Optimal Dose Usage to Reduce Recurrent Events-Seventh Organization to Assess Strategies in Ische- mic Syndromes (CURRENT-OASIS 7) trial evaluated a 600-mg clopidogrel loading dose followed by 7 days of 150 mg of clopidogrel in patients with acute coronary syndromes not selected by platelet function testing and found an increased risk of bleeding that required blood transfusion. 38 The discordant findings between that study and GRAVITAS may in part be explained by differences in the study populations: in the current trial, we enrolled patients with high on-treatment reactivity and excluded those with major bleeding around the time of the index PCI, while CURRENT-OASIS 7 enrolled patients prior to PCI without regard to the level of on-treatment reactivity.
Although GRAVITAS is the largest randomized trial to date of individualized antiplatelet therapy based on ex vivo platelet function testing, the desired power of our primary analysis was reduced because we observed only 50 events, yet anticipated 68 events to have greater than 80% power to detect a 50% relative risk reduction with our intervention. A treatment effect of highdose clopidogrel therefore cannot be excluded.
Our trial has several limitations. Although eligible to be enrolled, few patients in the trial had high-risk acute coronary syndromes (biomarkerpositive non-ST-elevation and STelevation myocardial infarction); accordingly, the results may not apply to such patients. We measured platelet reactivity and assigned study drug after PCI, and therefore could not assess the effectiveness of high-dose clopidogrel in reducing the incidence of periprocedural myocardial infarction. Our therapeutic intervention was a higher, fixed dose of clopidogrel, rather than a strategy of iterative-dose adjustment to "normalize" platelet reactivity to a specific target. The baseline characteristics of patients with and without high on-treatment reactivity differed greatly, as noted in previous, smaller studies. 7, [39] [40] [41] We did not adjust our analyses for these differences because of the large number of independent variables compared with the relatively small number of events. 42 Therefore, the current study cannot address whether ontreatment reactivity is an independent predictor of thrombotic risk. 14 In conclusion, high-dose clopidogrel for 6 months in patients with high on-treatment platelet reactivity 12 to 24 hours after PCI with drugeluting stents did not reduce the rate of death from cardiovascular causes, nonfatal myocardial infarction, or stent thrombosis compared with standard-dose clopidogrel. The results of GRAVITAS do not support a uniform treatment strategy of highdose clopidogrel in patients with high on-treatment reactivity identified by a single platelet function test after PCI. Alternative treatment strategies incorporating platelet function testing merit further investigation.
